Pharmacology of Protein-Based Therapies
Afsana Trini(Bristol-Myers Squibb (Belgium)), Vibha Jawa(Bristol-Myers Squibb (Belgium)), Glareh Azadi(Bristol-Myers Squibb (Germany)), Laxmikant Vashishta(Anthem Biosciences (India)), Kaushik Datta(Bristol-Myers Squibb (Germany))
Cited by 0
Related Papers
Re-evaluating the need for chronic toxicity studies with therapeutic monoclonal antibodies, using a weight of evidence approach
|Regulatory Toxicology and Pharmacology|2022|32
The use of recovery animals in nonclinical safety assessment studies with monoclonal antibodies: further 3Rs opportunities remain
|Regulatory Toxicology and Pharmacology|2023|15
Beyond MABEL: An Integrative Approach to First in Human Dose Selection of Immunomodulators by the Health and Environmental Sciences Institute (HESI) Immuno‐Safety Technical Committee (ITC)
|Clinical Pharmacology & Therapeutics|2024|15
Harmonized 3Rs-based non-mutagenic impurity qualification study designs developed using the results of an IQ consortium survey
|Regulatory Toxicology and Pharmacology|2021|13
Industry Perspective on First‐in‐Human and Clinical Pharmacology Strategies to Support Clinical Development of T‐Cell Engaging Bispecific Antibodies for Cancer Therapy
|Clinical Pharmacology & Therapeutics|2024|10